| abstract |
The present invention provides an antigen that contributes to the development of a safe and effective vaccine against mycoplasma pneumonia for which there is currently no effective preventive measure, and a vaccine using the antigen. Mycoplasma pneumoniae typified by S- (2,3-bispalmitoyloxypropyl) cysteinyl peptide and S- (2,3-bispalmitoyloxypropyl) -N-palmitoyl-cysteinyl peptide Synthetic lipopeptide derived from Mycoplasma pneumoniae, a toll-like receptor activator containing the lipopeptide, a transcription factor inducer containing the lipopeptide, the lipopeptide and a vaccine composition containing a pharmaceutically acceptable carrier object. [Selection] Figure 2 |